Challenge: Client sought to become a gene‑therapy leader, but the current R&D pipeline portfolio needed to capture external innovation to achieve its near and mid-term portfolio strategy. No prioritization of external assets or formation of a potential external pipeline was previously completed.
Approach: Scimitar developed a prioritized framework focused on clinical and commercial attractiveness, risk, and portfolio fit. A universe of >500 gene therapy programs were triaged with a TA-focused screening, followed by a disease-focused screening. Programs were tiered into categories that aligning with multi-year portfolio strategy.
Impact: Identified ~30 high‑priority assets across multiple disease areas across TAs, directly informing client’s in-licensing decisions for 2 recommended assets that materially strengthened their market position.
